Hello, Traders.
Every now and again, trade opportunities come across my desks and my sense of excitement begins to rise
...my pupils begin to expand
...my palms begin to sweat
...and, my heart beats a little faster.
It's because my intuition is telling me that I could be onto something with more potential than most trade ideas I'v seen in many days...possibly many weeks.
Now, that's the type of stock I could be introducing to you TODAY!

-------------------------------------------------------------

My Next Huge Biotech Stock is...

*** Echo Therapeutics (OTCBB: ECTE) ***



Echo Therapeutics is a transdermal medical device company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System as a platform technology for transdermal drug delivery.

ECTE believes that the Symphony tCGM System will change the paradigm of invasive, needle-based, pisodic glucose testing in the diabetes consumer and hospital critical care markets to one of continuous, eedle-free monitoring.

ECTE is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation to allow for transdermal drug delivery of a wide range of FDA-approved products.
ECTE believes that the Symphony system is an ideal solution for diabetics and critically ill patients allowing for continuous, pain-free monitoring of glucose levels.

The continuous monitoring will enable more accurate management of diabetes (resulting in healthier outcomes) and higher compliance compared to painful, invasive methods for drawing blood today.

ECTE also believes that its Prelude SkinPrep System will allow many drugs currently delivered by needle injection to be administered without a needle by using Prelude prior to transdermal drug administration.

----------------------------------
ECTE's $15 Million Agreement


ECTE has signed a $15 million agreement, giving Ferndale Pharmaceuticals a license to develop, market and sell Prelude for enhanced delivery of Ferndale’s topical lidocaine product, LMX4, in North America and the UK. Echo received $750,000 up front and will receive $750,000 upon FDA approval, as well as $12.5 million in milestones and guaranteed minimum royalty payments. Echo will also receive a double digit royalty on
net sales of the product.

------------------------------------------------
What is the Symphony™ tCGM System?



Non-invasive, wireless, continuous blood glucose monitoring system
Utilizes Prelude™ SkinPrep, a novel, needle-free platform technology that increases skin permeability
Efficient, remote monitoring platform compared to platforms using needle-basedtechnologies for accuracy
Low manufacturing cost and a razor/razor blade model with a single-use consumable
Readings obtained every minute with wireless data transmission to portable monitor
Short, one-hour warm-up
----------------------------------------------------


Product Pipeline


Six consecutive positive pilot studies in glucose monitoring to date
510-k filing in 1Q10 for Prelude with the use of lidocaine
Prelude lidocaine sales offer best near-term revenue opportunity
Minimum sales would reduce cash burn and move company toward cash flow positive business
Revenues projected to begin during 2Q10
Pivotal trial and PMA filing for Symphony™ anticipated in 2010 for glucose monitoring
Symphony™ tCGM licensed in South Korea to Handok Pharmaceuticals
---------------------------------------------

ECTE Could Be a High Growth Top-Shelf Pharmaceutical/Biotech Stock


I've mentioned that there are some stocks that perform extremely well because they are "Story Stocks" whose one-of-a-kind, unique technology is intriguing and special enough that it makes entertaining discussions for those not even involved in development-stage companies that are abundant in the OTC/OTCBB Markets.
And, there are other stocks that have highly compelling reasons from a technical viewpoint that suggest a profitable breakout could put traders into outstanding profit positions.
So, how does this relate to Echo Therapeutics (OTCBB: ECTE)? Simple...I believe that ECTE has both categories of trading philosophies in its corner, and that could be the ingredients for an explosive opportunity wherein the symbol could absolutely soar!

Watch ECTE trade...don't miss out!






Best Regards,

StockAlert@TheStockCents.com

www.TheStockCents.com

kcmh

Happy New Year!


This is a great day to be in the market! There are a lot of people on vacation right now but those that have stuck around to trade and invest are poised to potentially make some great returns once everyone is back next week.



We would like to introduce a little technical analysis lesson which I believe applies very well here.



This is an example of a Rounding Bottom which KCMH weekly chart is also displaying. This shows what the potential of KCMH could be!


(use roundingbot-example)
(use kcmhdec30weekly)





News came out this morning that shows that this move is just beginning!


Here are some of the highlights from PR.....

KCM HOLDINGS CORP. RECEIVES 2009 BEST OF BUSINESS AWARD
STILL DEBT-FREE & PROFITABLE - KCMH has remained debt free and profitable every quarter since its inception in 2007.
MARKETPLACE – The stock is starting to gain recognition and visibility in the marketplace. They anticipate increased volume, price-per-share, and a $100M+ market cap in 2010.
GEENIUS - Will be publicly trading in 1st Quarter 2010. KCMH owns 10% plus revenue sharing. The Geenius IPO will increase KCMH’s book value by millions of dollars.
EMPIRE RECORDINGS - Will be distributed by a major industry label to be announced on the near term horizon. Kevin Alexander, President and CEO, brings over 15 years of music experience, working with the biggest acts in the industry such as: The Black Eyed Peas, G-Unit, Dr. Dre, Eryka Badu, Eminem and Linkin Park.
KCM INSURANCE SERVICES – They expanded their already successful insurance division to include mortgage protection insurance coverage. 2010 gross revenue projections are between $5 and $6 million dollars.
CONTINUED DEVELOPMENT & COMMITMENT - They are committed to safeguarding the KCMH capital structure and increasing shareholder value and will continue to maintain that commitment indefinitely. They are currently in negotiations to add an alternative energy company and a custom motorcycle manufacturer to the KCMH portfolio.
PINKSHEETS - In late December KCMH was downgraded from "Current Information" Status to "Limited Information". They will have a legal opinion letter for 4Q 2009 submitted in early January 2010, and will return to "Current Information."
We wish everyone a very HAPPY NEW YEAR and MANY HAPPY RETURNS!